With 4-year data, Novo bolsters star power of obesity blockbuster Wegovy fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
The US Food and Drug Administration on March 8 approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke, or heart-related death in people at higher risk of these conditions.
The Centers for Medicare & Medicaid Services disclosed last week it will provide coverage for the popular weight loss drug Wegovy for patients at high risk for cardiovascular disease and stroke.
Obesity drug Wegovy is approved to cut heart attack and stroke risk in overweight patients gasiantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gasiantimes.com Daily Mail and Mail on Sunday newspapers.